Has Hamid Taheri, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,852,593 in general payments to Hamid Taheri, MD across 1,585 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Hamid Taheri, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Hamid Taheri, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Hamid Taheri, MD

Cardiovascular Disease · Manassas, VANPI 1295773679

Payments from drug & device makers

$4,852,593in general payments, 2019–2025

Across 1,585 payments — averaging $3061.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$2.9M
Amgen$395K
Eli Lilly$282K
Merck$243K
Astrazeneca UK Limited$222K
Johnson & Johnson$128K
plus $651K from 54 others

$2,707in research payments, 2019–2025

Across 1 payment — averaging $2706.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$3K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	109	$2,932,323
Amgen	141	$394,611
Eli Lilly	3	$282,184
Merck	59	$243,090
Astrazeneca UK Limited	2	$221,673
Johnson & Johnson	180	$127,524
Novo Nordisk	81	$108,085
Boehringer Ingelheim Pharma GmbH & Co.kg	6	$87,832
Boehringer Ingelheim International GmbH	8	$80,623
Alnylam Pharmaceuticals Inc.	25	$77,579
Esperion Therapeutics, Inc.	130	$71,055
Ionis Pharmaceuticals, Inc.	21	$59,764
Boehringer Ingelheim	123	$53,123
Abbott	40	$32,433
AstraZeneca	68	$23,504
Lilly USA, LLC	15	$17,719
Amarin Pharma, Inc.	35	$8,561
Sanofi US Services Inc.	1	$8,000
E.r. Squibb & Sons, L.L.C.	86	$4,269
Cardiovascular Systems Inc.	132	$3,882
Boston Scientific	24	$2,119
Abiomed	20	$1,803
Organon	1	$1,686
Medtronic(2 entities)	11	$1,048
Actelion Pharmaceuticals US, Inc.	35	$881
Pfizer	40	$828
Recor Medical Inc	12	$704
Edwards Lifesciences	7	$589
Heartflow, Inc.	7	$540
Scpharmaceuticals Inc.	17	$501
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	17	$475
Bayer	20	$418
Cvrx, Inc.	8	$393
Atricure, Inc.	9	$338
Bridgebio Pharma, Inc.	7	$248
Sanofi-aventis U.S. LLC	13	$222
Kestra Medical Technology Services, Inc.	5	$195
Philips North America LLC	5	$184
ZOLL Respicardia, Inc.	1	$136
Chiesi USA, Inc.	4	$127
Aegerion Pharmaceuticals, Inc.	8	$111
Daiichi Sankyo Inc.	6	$100
Regeneron Healthcare Solutions, Inc.	6	$95
Janssen Scientific Affairs, LLC	2	$95
Cook Medical LLC	3	$91
Qorumpartners	2	$79
Terumo Medical Corporation	2	$75
Baxter Healthcare	1	$58
Portola Pharmaceuticals, LLC	2	$58
Gilead	3	$55
Shockwave Medical, Inc	3	$54
Bard Peripheral Vascular, Inc.	1	$53
Kowa Pharmaceuticals America, Inc.	3	$51
W. L. Gore & Associates, Inc.	2	$47
Kiniksa Pharmaceuticals International, PLC	2	$43
Cordis US CORP.	1	$33
Lexicon Pharmaceuticals, Inc.	1	$33
Cardinal Health 200 LLC	1	$32
Livanova USA, Inc.	1	$25
Tactile Systems Technology Inc	1	$23

How this compares

$4,852,593 in reported general payments places this provider in the 95th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia →

Medicare billing

Part B allowed, 2024

$1,611,134

Medicare patients

1,520

Services billed

7,818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Manassas

Vikram PrasannaManassas$880K
Shahram YazdaniManassas$638K
Keith ChuManassas$464K
Khalid AbousyManassas$68K
Tariq HaddadFalls Church$8M
David LimCharlottesville$6M
Philip OdonnellWinchester$4.6M
Antonio AbbateCharlottesville$4M
George VetrovecRichmond$2.3M
Henry TranFalls Church$1.6M

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →